<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>In8bio Inc — News on 6ix</title>
    <link>https://6ix.com/company/in8bio-inc</link>
    <description>Latest news and press releases for In8bio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 03 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/in8bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583ac78dffbe2df0fccaf.webp</url>
      <title>In8bio Inc</title>
      <link>https://6ix.com/company/in8bio-inc</link>
    </image>
    <item>
      <title>IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
      <description>NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ</description>
    </item>
    <item>
      <title>IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-durable-survival-improvements-in-glioblastoma-advancing-pipeline-and-strengthened-financial-position-for-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-reports-fourth-quarter-and-full-year-2025-financial-results-highlights-durable-survival-improvements-in-glioblastoma-advancing-pipeline-and-strengthened-financial-position-for-2026</guid>
      <pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
      <description>Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI”) nearly doubling median progression-free survival (“mPFS”) to 13.0 months versus 6.6 months in a contemporaneous standard-of-care control cohort (+97%) Closed initial $20.1 million tranche of a private placement of up to $40.2 million in gross proceeds; net proceeds extend cash r</description>
    </item>
    <item>
      <title>IN8bio to Present at TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-to-present-at-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-to-present-at-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to</description>
    </item>
    <item>
      <title>IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-promotes-kate-rochlin-ph-130000582</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-promotes-kate-rochlin-ph-130000582</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>Photo Kate Rochlin, Ph.D., President &amp; COO NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately. Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice Presid</description>
    </item>
    <item>
      <title>IN8bio to Present at Upcoming Investor and Scientific Conferences in February</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-present-upcoming-investor-scientific-130000022</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-present-upcoming-investor-scientific-130000022</guid>
      <pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity ConferenceDate: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation:</description>
    </item>
    <item>
      <title>IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-presents-updated-phase-ii-130000489</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-presents-updated-phase-ii-130000489</guid>
      <pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
      <description>Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocolMedian overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several patients who remain progression-free for multiple years (1.4 – 4.6 years) compared to only 13.2 months for SOC (+30.3%)Trea</description>
    </item>
    <item>
      <title>IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-announces-pricing-private-placement-130000516</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-announces-pricing-private-placement-130000516</guid>
      <pubDate>Fri, 19 Dec 2025 13:00:00 GMT</pubDate>
      <description>$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical com</description>
    </item>
    <item>
      <title>IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-reports-third-quarter-2025-210000378</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-reports-third-quarter-2025-210000378</guid>
      <pubDate>Thu, 06 Nov 2025 21:00:00 GMT</pubDate>
      <description>Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety profileExpanded Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State University, supporting faster enrollment to complete the Phase 1 expansion cohortContinued to advance IN8bio’s</description>
    </item>
    <item>
      <title>IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-expands-inb-100-phase-120000349</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-expands-inb-100-phase-120000349</guid>
      <pubDate>Wed, 29 Oct 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company’s INB-100, a donor-derived allogeneic gamma-delta T cell therapy for patients with leukemias undergoing haploidentical stem cell transplantation. The addition of this l</description>
    </item>
    <item>
      <title>IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-presents-t-cell-engager-120000888</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-presents-t-cell-engager-120000888</guid>
      <pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
      <description>INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B cell depletion.INB-619 is the first pan-gamma delta (γδ) T cell engager designed to significantly expand multiple γδ T cell subsets for efficient, durable target elimination.INB-619 achieved robust γδ T cell expansion and complete B cell depletion a</description>
    </item>
    <item>
      <title>IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-reports-second-quarter-2025-200000965</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-reports-second-quarter-2025-200000965</guid>
      <pubDate>Thu, 07 Aug 2025 20:00:00 GMT</pubDate>
      <description>Delivered an oral presentation at ASCO 2025 Annual Meeting, demonstrating extended median progression-free survival (mPFS) in patients receiving multiple doses of INB-200, including a patient remaining progression-free for over four years.Received the Host Region USA East Abstract Award at ISCT 2025 for IN8bio’s DeltEx™ manufacturing platform.Presented preclinical data at ASGCT 2025 on INB-619, a novel gamma-delta T cell engager, and its ability to induce pan-gamma-delta T cell expansion and tar</description>
    </item>
    <item>
      <title>IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-recognizes-achievement-4-years-110000400</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-recognizes-achievement-4-years-110000400</guid>
      <pubDate>Mon, 09 Jun 2025 11:00:00 GMT</pubDate>
      <description>Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trialNEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recently r</description>
    </item>
    <item>
      <title>IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-presents-positive-phase-1-113000334</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-presents-positive-phase-1-113000334</guid>
      <pubDate>Mon, 02 Jun 2025 11:30:00 GMT</pubDate>
      <description>Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-20</description>
    </item>
    <item>
      <title>IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-presents-preclinical-data-highlighting-120000616</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-presents-preclinical-data-highlighting-120000616</guid>
      <pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
      <description>Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in patients with chronic disease a</description>
    </item>
    <item>
      <title>IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-presents-data-isct-2025-120000525</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-presents-data-isct-2025-120000525</guid>
      <pubDate>Mon, 12 May 2025 12:00:00 GMT</pubDate>
      <description>Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-sta</description>
    </item>
    <item>
      <title>IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-reports-first-quarter-2025-200000147</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-reports-first-quarter-2025-200000147</guid>
      <pubDate>Wed, 07 May 2025 20:00:00 GMT</pubDate>
      <description>Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation &amp; Cellular Therapy (TCT) Meetings On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multipl</description>
    </item>
    <item>
      <title>IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-present-clinical-preclinical-data-120000930</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-present-clinical-preclinical-data-120000930</guid>
      <pubDate>Tue, 29 Apr 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences. “The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bi</description>
    </item>
    <item>
      <title>IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-unveils-promising-data-next-120000932</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-unveils-promising-data-next-120000932</guid>
      <pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
      <description>First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS)INB-600 TCE platform significantly expands both Vδ1+ and Vδ2+ subsets to address the reduced cell counts that have limited earlier γδ TCE therapies in cancer patientsINB-619 (CD19) and INB-633 (CD33) consistently show potent and highly targeted anti-cancer activi</description>
    </item>
    <item>
      <title>IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-present-preclinical-data-novel-120000657</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-present-preclinical-data-novel-120000657</guid>
      <pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced today a poster presentation on its potentially breakthrough next generation γδ T cell-based T cell engager (TCE) platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL. “T cell engagers are an exciting area of</description>
    </item>
    <item>
      <title>IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025</title>
      <link>https://6ix.com/company/in8bio-inc/news/in8bio-participate-11th-annual-immuno-120500823</link>
      <guid isPermaLink="true">https://6ix.com/company/in8bio-inc/news/in8bio-participate-11th-annual-immuno-120500823</guid>
      <pubDate>Tue, 18 Mar 2025 12:05:00 GMT</pubDate>
      <description>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on</description>
    </item>
  </channel>
</rss>